Report Tools

Biotechnology in Germany

Published: August 2013 · Publisher: MarketLine
Biotechnology in Germany industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017).
Report Type Industry Profiles
Language English
Format Electronic (PDF)
Pages33
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-6781
Price € 259,00
Options
  • Description
  • Companies Mentioned
  • Table of Contents
  • Ask a Question
Introduction

Biotechnology in Germany industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Germany biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.

*The German biotechnology market had total revenues of $7.7bn in 2012, representing a compound annual growth rate (CAGR) of 8.7% between 2008 and 2012.

*In 2012 many companies in Europe were still preoccupied with matters of efficiency and raising funds in a difficult financing environment. These though conditions are however expected to ease going forward, which should facilitate good market growth.

*The performance of the market is forecast to decelerate, with an anticipated CAGR of 7.8% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $11.2bn by the end of 2017.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Germany

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Germany

Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Germany biotechnology market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Germany economy

Key Questions Answered

What was the size of the Germany biotechnology market by value in 2012?

What will be the size of the Germany biotechnology market in 2017?

What factors are affecting the strength of competition in the Germany biotechnology market?

How has the market performed over the last five years?

What are the main segments that make up Germany's biotechnology market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Boehringer Ingelheim GmbH, Merck & Co., Inc. and MorphoSys AG
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Boehringer Ingelheim GmbH 19
Merck & Co., Inc. 23
MorphoSys AG 26
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related research 32

LIST OF TABLES
Table 1: Germany biotechnology market value: $ billion, 2008–12 8
Table 2: Germany biotechnology market category segmentation: $ billion, 2012 9
Table 3: Germany biotechnology market geography segmentation: $ billion, 2012 10
Table 4: Germany biotechnology market value forecast: $ billion, 2012–17 11
Table 5: Boehringer Ingelheim GmbH: key facts 19
Table 6: Boehringer Ingelheim GmbH: key financials ($) 20
Table 7: Boehringer Ingelheim GmbH: key financials (€) 20
Table 8: Boehringer Ingelheim GmbH: key financial ratios 21
Table 9: Merck & Co., Inc.: key facts 23
Table 10: Merck & Co., Inc.: key financials ($) 24
Table 11: Merck & Co., Inc.: key financial ratios 24
Table 12: MorphoSys AG: key facts 26
Table 13: MorphoSys AG: key financials ($) 27
Table 14: MorphoSys AG: key financials (€) 27
Table 15: MorphoSys AG: key financial ratios 27
Table 16: Germany size of population (million), 2008–12 29
Table 17: Germany gdp (constant 2000 prices, $ billion), 2008–12 29
Table 18: Germany gdp (current prices, $ billion), 2008–12 29
Table 19: Germany inflation, 2008–12 30
Table 20: Germany consumer price index (absolute), 2008–12 30
Table 21: Germany exchange rate, 2008–12 30

LIST OF FIGURES
Figure 1: Germany biotechnology market value: $ billion, 2008–12 8
Figure 2: Germany biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: Germany biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: Germany biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in Germany, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in Germany, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in Germany, 2012 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in Germany, 2012 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in Germany, 2012 17
Figure 10: Drivers of degree of rivalry in the biotechnology market in Germany, 2012 18
Figure 11: Boehringer Ingelheim GmbH: revenues & profitability 21
Figure 12: Boehringer Ingelheim GmbH: assets & liabilities 22
Figure 13: Merck & Co., Inc.: revenues & profitability 25
Figure 14: Merck & Co., Inc.: assets & liabilities 25
Figure 15: MorphoSys AG: revenues & profitability 28
Figure 16: MorphoSys AG: assets & liabilities 28
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.